Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01532570) looked at a treatment for Behçet's disease (BD), a rare condition that can cause inflammation in different parts of the body. A total of 18 people took part, divided into four groups based on which part of their body was affected: 11 with intestinal BD, 2 with acute neurological BD, 1 with chronic progressive neurological BD, and 4 with vascular BD. The main thing the trial was measuring was how many participants in each group showed a "complete response" by week 30 — meaning their symptoms had disappeared and scans and laboratory markers had improved compared to the start of the trial. The reported data shows that, at week 30, the complete response rate was 54.5% in the intestinal BD group (roughly 6 out of 11 people), 0% in the acute neurological BD group (neither of the 2 participants met the criteria), 100% in the chronic progressive neurological BD group (the 1 participant), and 100% in the vascular BD group (all 4 participants). At the earlier check-in point of week 14, the numbers were the same across all groups, and at week 54 they were similar — 60% for intestinal BD, 0% for acute neurological BD, and 100% for both the chronic progressive neurological and vascular BD groups. It is worth noting that the neurological and vascular groups were very small (1–4 people), so these percentages represent only a handful of individuals. The reported data also shows that participants rated their own symptoms on a scale of 0 (best) to 100 (worst) at several time points. Across all groups, the self-reported scores appeared to decrease over the course of the study — for example, the intestinal BD group started at around 55.5 and reached around 23.6 at the final measurement point, while the vascular BD group went from about 40.5 down to about 14.3. Imaging results for intestinal ulcers and brain MRI findings were also recorded, though the very small numbers in the neurological groups make these figures difficult to interpret broadly. Some imaging data points were not broken down in full detail in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27310969) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Behcet's disease (either the full or partial form) based on Japanese Ministry of Health guidelines.
- You have serious complications of Behcet's disease (called "special lesions") that have not responded to standard treatments, or you are unable to tolerate those standard treatments.
- You are currently experiencing symptoms related to these serious complications of Behcet's disease.
Who may not be able to join:
- You have a form of Behcet's disease affecting the intestines, nervous system, or blood vessels, and doctors are not yet certain whether your condition is definitely Behcet's disease or something else (confirm with trial site).
- You have been treated with a medication called infliximab in the past year for a reason other than treating your Behcet's disease complications, or you previously had to stop taking infliximab because of side effects.
- You have taken part in another clinical trial and received a trial medication within the past 12 weeks.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With Complete Response at Week 30
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.